文献速递胸部肿瘤

EGFR突变早期非小细胞肺癌的围手术期治疗策略:当前证据与未来挑战

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
PubMed 文献 · J Thorac Oncol · 2023-09-30

完全切除的I-IIIA期伴常见敏化EGFR突变的NSCLC患者中,3年辅助奥希替尼治疗被视为新标准,较安慰剂显著延长无病生存期和总生存期,并在预防脑转移方面起重要作用。但最佳治疗时长、是否所有患者均获益、辅助化疗的作用等问题尚未解决,新辅助靶向策略也重新受到关注。

要点

  • 完全切除的I-IIIA期伴常见敏化EGFR突变NSCLC,3年辅助奥希替尼为新生标准。
  • 辅助奥希替尼较安慰剂显著延长无病生存期和总生存期,并显著预防脑转移。
  • 最佳治疗时长、全部患者是否获益及辅助化疗作用等临床挑战仍待解决。

核心结论

  • 3年辅助奥希替尼被视为完全切除的I-IIIA期伴常见敏化EGFR突变NSCLC患者的新标准治疗。

研究设计与样本

  • 本文为综述,讨论EGFR突变早期NSCLC围手术期治疗策略的过去与当前治疗选择及临床挑战。

主要发现

  • 辅助奥希替尼较安慰剂显著延长无病生存期和总生存期,并在预防脑转移方面起显著作用。

局限性

  • 最佳治疗时长、是否所有患者均从辅助奥希替尼获益、辅助化疗在该人群中的作用等许多问题仍未解答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment with 3 years of adjuvant osimertinib is considered a new standard in patients with completely resected stage I to IIIA NSCLC harboring a common sensitizing EGFR mutation. This therapeutic approach significantly prolonged the disease-free survival and the overall survival versus placebo and revealed a significant role in preventing the occurrence of brain metastases. However, many unanswered questions remain, including the optimal duration of this therapy, whether all patients benefit from adjuvant osimertinib, and the role of adjuvant chemotherapy in this population. Indeed, there is a renewed interest in neoadjuvant strategies with targeted therapies in resectable NSCLC harboring oncogenic drivers. In light of these considerations, we discuss the past and current treatment options, and the clinical challenges that should be addressed to optimize the treatment outcomes in this patient population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Remon J, Saw SPL, Cortiula F, et al. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges. J Thorac Oncol. 2023. PMID: 37783386. doi:10.1016/j.jtho.2023.09.1451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。